2 results
Approved WMOPending
Primary objectivesDetermine the effect of Sorafenib (Bay 43-9006) on the uptake of In-111 labeled chimeric monoclonal antibody G250 (In-111-cG250) by RCC lesions.Determine the effect of Sorafenib (Bay 43-9006) on the uptake of In-111 labeled…
Approved WMOPending
Primary Objective: To evaluate potential changes in body composition and REE after NMES therapy at home for 12 weeks.We hypothesize that NMES therapy would result in hypertrophy of gluteal and hamstring muscles, and an increase in LL-LBM, total LBM…